Holen Sie sich die Stockscreener-App
283.34
11.75%
29.79
Schlusskurs vom Vortag:
$253.54
Offen:
$261.82
24-Stunden-Volumen:
3.11M
Relative Volume:
4.49
Marktkapitalisierung:
$36.68B
Einnahmen:
$2.25B
Nettoeinkommen (Verlust:
$-278.16M
KGV:
-130.57
EPS:
-2.17
Netto-Cashflow:
$-42.59M
1W Leistung:
+17.20%
1M Leistung:
+13.07%
6M Leistung:
+3.45%
1J Leistung:
+93.25%
1-Tages-Spanne:
$261.00
$289.44
1-Wochen-Bereich:
$240.94
$289.44
52-Wochen-Spanne:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam Expanded Heart Drug Approval Sets Up Pfizer Challenge - MSN
Alnylam price target raised to $338 from $300 at Scotiabank - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: RNAi leader’s stock poised for growth in ATTR-CM market - Investing.com
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer - MSN
Alnylam Stock Jumps After the FDA Approves Its Heart Drug - The Wall Street Journal
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (NASDAQ:ALNY) - Seeking Alpha
U.S. Markets Moved Upward Friday; Alnylam Pharmaceuticals Climbed Highest - Barron's
Buy, Sell, Or Hold Alnylam Stock At $280? - Forbes
Check Out What Whales Are Doing With ALNY - Benzinga
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Alnylam Pharma Stock (ALNY) Rockets on FDA Drug Approval - TipRanks
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy - TradingView
Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects - MSN
Alnylam prices heart drug at premium to rivals - BioPharma Dive
Alnylam's Amvuttra Gains Expanded US Approval for Heart ConditionNews and Statistics - IndexBox, Inc.
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating - Marketscreener.com
Alnylam Pharmaceuticals Shares Rise After Receipt of US FDA Approval for ATTR-CM Drug - Marketscreener.com
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - Yahoo Finance
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
Sector Update: Health Care -March 21, 2025 at 09:20 am EDT - Marketscreener.com
Sector Update: Health Care - TradingView
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating - Marketscreener.com
Alnylam scores a first with FDA nod for Amvuttra in ATTR-CM - The Pharma Letter
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Alnylam stock rises after FDA nod for AMVUTTRA By Investing.com - Investing.com Canada
Alnylam joins three-way contest in ATTR cardiomyopathy - pharmaphorum
Alnylam’s SWOT analysis: biotechnology stock poised for growth amid ATTR-CM market expansion - Investing.com
Alnylam Pharmaceuticals Recieives US FDA Approval for ATTR-CM Drug -March 21, 2025 at 03:59 am EDT - Marketscreener.com
Alnylam drug gets long-awaited FDA approval in deadly heart disease - BioPharma Dive
FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy - CGTLive™
Alnylam nabs key additional indication for Amvuttra - MSN
Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - Citeline
US FDA expands approval for Alnylam's drug to treat rare heart disease - Reuters
Alnylam wins FDA approval for rare heart disease drug - The Business Journals
FDA approves first dual-action treatment for ATTR amyloidosis - Investing.com India
Amvuttra’s label expansion lifts Alnylam toward five-year goals - BioCentury
US FDA expands approval for Alnylam's drug to treat rare heart disease -March 20, 2025 at 06:04 pm EDT - Marketscreener.com
US FDA approves Alnylam's drug for rare heart condition - Marketscreener.com
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) -March 20, 2025 at 05:57 pm EDT - Marketscreener.com
US FDA approves Alnylam's drug for rare heart condition -March 20, 2025 at 05:56 pm EDT - Marketscreener.com
Breakthrough: New FDA-Approved Heart Disease Drug Cuts Death Risk by 36% - StockTitan
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Galveston County Daily News
Free genetic testing for AHP offered by Alnylam Act in US, Canada - Porphyria News
Ahead of FDA decision, Alnylam faces the big question: Can it make money? - Endpoints News
Alnylam at Stifel’s 2025 CNS Forum: Advances in RNAi for Neurological Diseases - Investing.com
Alnylam Pharmaceuticals To Present At Stifel 2025 Virtual CNS Forum; Webcast At 3:00 PM ET - Nasdaq
Arbor raises $74M amid genetic medicine’s funding slump - BioPharma Dive
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space - BioSpace
How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHULMAN AMY W | Director |
Mar 13 '25 |
Option Exercise |
131.21 |
2,750 |
360,828 |
11,186 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 03 '25 |
Sale |
243.73 |
1,911 |
465,772 |
14,345 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '25 |
Sale |
241.15 |
844 |
203,532 |
13,501 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 03 '25 |
Sale |
243.78 |
471 |
114,820 |
28,011 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 03 '25 |
Sale |
243.79 |
1,749 |
426,384 |
25,350 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Mar 04 '25 |
Sale |
241.05 |
808 |
194,766 |
24,542 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 03 '25 |
Sale |
243.78 |
1,264 |
308,141 |
47,751 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 03 '25 |
Sale |
243.79 |
3,877 |
945,165 |
98,635 |
0.32%
4.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):